Search Results

You are looking at 101 - 110 of 550 items for :

  • Refine by Access: All x
Clear All
Full access

CLO22-065: Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach

John Mascarenhas, Arianna Kee, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry, and Ali McBride

consensus statements suggest patient-reported symptoms of fatigue, poor concentration, inactivity, and bone pain were too general to define RUX failure compared with other specific MF symptoms ie, night sweats. Following RUX failure, consensus

Full access

CLO23-060: Extranodal Presentation of Double Hit High Grade B Cell Lymphoma

Ernesto Munoz and Allison Carilli

, fatigue, and CNS involvement. This case illustrates a patient with disease involvement of the muscles of the forearm causing compartment syndrome. This is a rare presentation that have not been described in the literature to this date.

Full access

HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience

Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia

(others were on clinical trials with novel agents). Most common grade 3+ tox reported by providers included nausea (10%) and neuropathy (8%), while the common clinically significant tox reported by pts were neuropathy (20%), fatigue (20%), and anxiety (15

Full access

HSR20-106: Quantifying Patient Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Brian Seal, Candice Yong, M. Janelle Cambron-Mellott, Oliver Will, Martine C. Maculaitis, Kelly Clapp, Emily Mulvihill, Ion Cotarla, and Ranee Mehra

%, and all G neuropathy from 5% to 39%, if OS increased by 17, 4, and 2 months, respectively. In addition, pts would require an increase in OS of 1 month to accept an increase in G3/4 fatigue from 1% to 12% or all G pneumonitis from <1% to 8%. Preferences

Full access

QIM21-084: Perceived Needs and Patient Satisfaction of Psychosocial Distress Screening and Management in Inpatient Hematology Oncology Specialty Care

Chao-Hui Sylvia Huang, Jennifer K. Anderson, Jasmine A. Boykin, Jasmine K. Vickers, Heather Forbes, Kellie L. Flood, Lisle M. Nabell, and Kelly N. Godby

strategies to manage anxiety or depression. Barriers to receive counseling services include physical symptom burden such as pain and fatigue, medical procedures, and inadequate psychosocial care staffing. Findings revealed high perceived needs and patient

Full access

Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives

John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella

, available online, in this article, at www.JNCCN.org ) Nausea and Vomiting Management Barriers Questionnaire (NVMBQ) were developed using the Fatigue Management Barriers Questionnaire (FMBQ) 16 as a template. Patient-related barriers to communicating about

Full access

Role of Adjuvant and Posttreatment Exercise Programs in Breast Health

Jennifer A. Ligibel

diagnosis have lower rates of recurrence and death compared with sedentary individuals. A growing number of exercise intervention studies show that increased physical activity after diagnosis leads to improvements in quality of life, fatigue, and body image

Full access

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy

David D. Chism

-related AEs (TRAEs) included fatigue, pneumonitis, rash, and dyspnea. Among the 119 cisplatin-ineligible patients in cohort 1 who received atezolizumab in the first-line setting, there was an ORR of 23% (95% CI, 16–31) and a CR of 9%, with durable responses

Full access

Distress Screening and the Integration of Psychosocial Care Into Routine Oncologic Care

Jimmie C. Holland

-report was considered totally invalid,” explained Dr. Holland. To begin to measure subjective symptoms, validated, quantitative tools were developed in the 1970s and 1980s. Scales focused on items such as health-related quality of life, pain, fatigue

Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

show superiority. The toxicities differed between arms; more grade 3/4 thrombocytopenia (23.3% vs 5.6%), anemia (14.5% vs 2.7%), and fatigue (10.9% vs 5.0%) were seen in the pemetrexed group, whereas more grade 3/4 neutropenia (40.6% vs 25.8%), febrile